The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, 453100, China
NCT Number: NCT06785714
The primary objective of this study is to evaluate the sensitivity of the fecal protein dual-index test reagent for the detection of colorectal cancer (CRC).
Looking for future studies?
Notify Me45 year–74 year
All sexes
Observational
Xinxiang, Henan, 453100, China
The project uses fecal hemoglobin and transferrin dual-index combined with reagents that can be self-tested at home (referred to as fecal protein dual-index detection reagents), combined with colorectal cancer risk factor questionnaires, to carry out colorectal cancer screening in people of specific ages in the city, aiming to achieve early screening, early diagnosis and early treatment, and evaluate the effect of fecal protein dual-index detection reagents in early screening of colorectal cancer, so as to provide a scientific basis for optimizing the national screening program.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 180 days
Sensitivity of colorectal cancer detection
Time frame: 180 days
Specificity of advanced neoplasia detection
Time frame: 180 days
Positive predictive value of colorectal cancer detection
Time frame: 180 days
Negative predictive value of colorectal cancer detection
Time frame: 180 days
Sensitivity and specificity of advanced adenoma detection
The First Affiliated Hospital of Xinxiang Medical College
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT07725692
Anastomotic Leak, Colon Cancer
Alexandria, Please Select, Egypt
View Trial DetailsNCT07180303
Colonic Diseases, Colorectal Cancer
Liyang, Jiangsu, China
View Trial DetailsNCT03958747
Colonic Diseases, Colorectal Cancer
Winston-Salem, North Carolina, United States
View Trial Details